ZBH · Zimmer Biomet Holdings, Inc
Price
Snapshot
50 fields · last close| Market Cap | $18.37B |
| P/E | 23.50 |
| Float | 193.1M |
| Beta | 0.50 |
| Volatility | 12.6% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 79 |
| Price | 98.37 |
| Change | −0.56% |
| Prev Close | 98.92 |
| Open | 100.06 |
| Day Low | 98.15 |
| Day High | 101.81 |
| Avg Vol | 1 |
| Avg $ Vol | $131.1M |
| 52W High | 106.88 |
| 52W Low | 79.12 |
| 52W Pos | 69.3% |
| From High | −7.96% |
| From Low | +24.33% |
| Max DD 1Y | −24.73% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −1.06% |
| SMA 50 | +3.78% |
| SMA 200 | +7.72% |
| RSI (14) | 52.7 |
| Vol 30D | 25.7% |
| Vol 90D | 35.6% |
| 1Y Range | 79–107 |
| Daily bars | 506 |
| Perf Week | −0.56% |
| Perf Month | +0.77% |
| Perf Quarter | +14.11% |
| Perf Half Y | +5.85% |
| Perf Year | −5.83% |
| Perf YTD | +9.28% |
| Prev Day | −0.56% |
| Clavix | B+ |
| Debt / Eq | 0.59 |
| Curr Ratio | 1.98 |
| Int Cover | 4.2× |
| FCF Margin | 13.2% |
| Rev Growth | +4.8% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 16 / 47 |
What ZBH does
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide.
The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest.
It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues.
It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups.
It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care.
The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015.
Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Clavix risk grade
regraded every trading dayZBH grades B+, 79 of 100. Steadiest on Macro Resilience (70), most exposed on Price Stability (61, mixed). 2 of the 4 weighted dimensions sit above the Health Care median. Ranks 16 of 47 in Health Care by Clavix score.
How rough the ride is
| ZBH | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.50 | 0.81 |
| Volatilityannualized | 12.6% | 20.4% |
| Max drawdown, past yearworst peak-to-trough fall | −24.7% | — |
| Typical daily movemedian absolute daily change | 1.05% | — |
| Days beyond ±3%of the last 252 sessions | 198% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| ZBH | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.50 | 0.81 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Moderate55% of 47 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| ZBH | |
|---|---|
| 1 week | −0.6% |
| 1 month | +0.8% |
| Year to date | +9.3% |
| 1 year | −5.8% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| ZBH | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 29 Jul |
| Average score0 most bearish, 100 most bullish | 69 |
| Bullish · bearisharticles above 60 · below 40 | 25 · 0 |
| Directionarticles whose tone is improving vs worsening | 25 ↑ 0 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 47 Health Care names Clavix covers; the tick is the sector median.
Growth
| ZBH | |
|---|---|
| Revenue growthyear over year | +4.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Health Care
47 companies| Metric | ZBH | Sector spread | Median |
|---|---|---|---|
| Beta | 0.50 | 0.81 | |
| Volatility | 12.6% | 20.4% | |
| P/E | 23.50 | 26.14 | |
| Debt / equity | 0.59 | 0.71 | |
| Current ratio | 1.98 | 1.58 | |
| FCF margin | 13.2% | 8.6% | |
| Interest coverage | 4.2× | 6.3× |
Recent news
most recent scored articles · the chip is the article’s score · click to openZimmer Biomet is starting to show steady sales growth at constant exchange rates (i.e. ignoring currency swings), helped by its internal transformation program, new product development, and acquisitions. Earnings are growing more slowly than sales, but the article suggests this gap should close.
Zimmer Biomet's Board of Directors approved a quarterly cash dividend to stockholders for the third quarter of 2026. The article body is cut off, so the per-share amount, record date, and payment date are not shown.
Zimmer Biomet said its Board of Directors approved a quarterly cash dividend for the third quarter of 2026. The announcement did not include the per-share amount, record date, or payment date.
Zacks Research upgraded Zimmer Biomet (ZBH) from a 'strong sell' rating to a 'hold' rating in a research note on Tuesday.
The article weighs whether to hold Zimmer Biomet (ZBH), noting that growth is supported by healthy demand for medical procedures and growing use of its Z1, HAMMR, and OrthoGrid products, while flagging debt and competition as ongoing concerns.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| THC | Tenet Healthcare Corp | B- | $21.22B | 9.47 | 1.22 | Compare |
| SOLV | Solventum Corp | B+ | $15.74B | 10.26 | 0.72 | Compare |
| GH | Guardant Health Inc | C+ | $21.61B | — | 1.73 | Compare |
| STE | STERIS plc | A- | $22.12B | 27.69 | 0.88 | Compare |
| COO | Cooper Companies Inc | A- | $13.78B | 57.71 | 0.81 | Compare |
| BAX | Baxter International Inc | B | $13.22B | — | 0.67 | Compare |
| DGX | Quest Diagnostics Inc | A- | $26.42B | 24.97 | 0.56 | Compare |
| PEN | Penumbra Inc | A+ | $12.65B | 78.99 | 0.71 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.